PerkinElmer Joins High-Content Screening Fray With $30.5M Evotec Technologies Buy | GenomeWeb
PerkinElmer will acquire Evotec Technologies, the tools and technologies division of German drug-discovery firm Evotec, for €23 million ($30.5 million) in cash, the companies said this week.
 
The acquisition, expected to close at the end of this year or at the start of 2007, will give PerkinElmer an immediate competitive position in the high-content screening and cellular analysis markets, an area in which it had been conspicuously lagging behind its competitors.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.